CompletedNot Applicable

Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis

France100 participantsStarted 2013-11-19

Plain-language summary

The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Patients' inclusion criteria: * Adults aged ≥18 years-old * Hospitalized for hematological malignancy or hematopoietic stem cell transplantation * Recent (\>2months), prolonged (\>10 days), profound (\>100 PMN/mm3), feverish neutropenia * Suspected hepatosplenic candidiasis (typical small nodular lesions on abdominal RMI or CT) Patients' exclusion criteria: \- hepatosplenic lesions of other proven origin Patients' non-inclusion criteria: * Life expectancy \>3 months * Pregnancy * HIV infection * Hepatic biopsy within 3 weeks before 18F-FDG PET scan

What they're measuring

Global response to therapy

Timeframe: at month 3

Trial details

NCT IDNCT01916057

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-06-01

View on ClinicalTrials.gov More Invasive Fungal Disease trials